David Liu

In July 2021 Liu raised $315 million to launch Prime Medicine, which aims to use prime editing, a DNA-rewriting method developed in his Broad Institute lab, to treat rare genetic diseases. It’s the sixth startup co-founded by Liu, who has invented multiple tools for precision genetic medicine. Another, Beam Therapeutics, advanced several research programs last year using base editing (a way to reverse the single-point DNA mutations behind many diseases) to help patients with sickle cell disease produce normal hemoglobin.

From STAT:

• You had questions for David Liu about CRISPR, prime editing, and advice to young scientists. He has answers
• Scientists unveil the ‘most clever CRISPR gadget’ so far
• New CRISPR tool has the potential to correct almost all disease-causing DNA glitches, scientists report